The most useful way to examine Mondae is to follow the patient’s information, prescription and payment through the service. An online questionnaire starts the process, a contracted clinician decides whether treatment is appropriate, and an outside pharmacy dispenses any prescribed medication. Those are separate responsibilities, even when they appear within one website. Mondae describes the broad sequence clearly enough to understand its model, but its public documentation leaves several handoffs less defined: which pharmacy will dispense, what the first charge covers, when medication should arrive and how quickly clinical questions receive answers.
This review examines Mondae’s public documentation consulted October 19, 2026, rather than firsthand treatment or independently verified clinical operations. The company advertises compounded semaglutide and compounded tirzepatide, nationwide availability and direct payment without insurance. Its product pages also list sermorelin, NAD+ and glutathione injections. For adults comparing care arrangements, the central question is not simply whether Mondae offers an online prescription pathway. It is whether the documented responsibilities, communication channels and financial terms are sufficiently clear before enrollment—and which details should be obtained in writing before moving forward.
At a glance
- Platform and clinical responsibility
- Mondae LLC operates the website. Its terms say Mondae does not provide medical services and that telehealth care is provided through Bask Telehealth LLC and contracted physicians.Sources: [9]
- Advertised GLP-1 prices
- The homepage advertises compounded semaglutide from $69/month and compounded tirzepatide from $114/month. Product pages show $87/month and $126/month, respectively, without clearly tying those amounts to a displayed plan length.
- Payment model
- Mondae and its providers describe the service as cash-pay, outside commercial insurance and government programs such as Medicare and Medicaid.Sources: [9]
- Delivery and follow-up
- Mondae advertises home delivery with tracking and secure provider messaging through its patient portal, but the consulted documentation does not establish arrival deadlines or clinical response times.Sources: [3]
- Cancellation boundary
- Orders may be canceled only before medication has been dispensed or shipped. Consultation fees are described as nonrefundable, including when no medication is prescribed.Sources: [2]
Who is responsible at each step?
Mondae LLC owns and operates the website, but its terms explicitly separate the platform from medical practice. They say medical services come through a contracted network of physicians licensed in the patient’s state, with telehealth services provided through Bask Telehealth LLC. The terms give Bask a mailing address at 555 Madison Ave., Suite 1202, New York, NY 10022. These disclosures identify organizations within the care pathway; they do not independently verify a particular clinician’s credentials or establish who will handle an individual case.
The homepage similarly describes Mondae as a platform connecting eligible patients with licensed healthcare providers. It says Mondae neither manufactures medications nor determines which medication is appropriate. Those decisions belong to the treating professional after reviewing the patient’s history, eligibility and goals. Our guide to clinicians and telehealth platforms explains why that distinction matters: administrative support, prescribing decisions and dispensing questions may need to go to different people, even if the initial purchase experience feels unified.
Mondae also says prescriptions come from state-licensed U.S. clinicians and are dispensed by licensed U.S. pharmacies. However, the consulted documentation does not name the dispensing pharmacies or allow independent verification of individual professional licenses. Before paying, a useful request is the name of the clinical organization responsible for care, how the assigned prescriber will be identified, and when the dispensing pharmacy’s identity and contact details will become available.
From questionnaire to a prescribing decision
Mondae says enrollment begins with a secure online questionnaire covering medical history, current medications and treatment goals. A U.S.-licensed healthcare provider then reviews the information and conducts a medical consultation to decide whether treatment is appropriate. The product documentation states that a prescription is required and will be issued only when medically appropriate. Completing intake therefore does not establish eligibility or guarantee medication. The consulted pages do not specify whether every consultation occurs through video, telephone or another format.
Several practical parts of the assessment remain undocumented: required tests, specific clinical eligibility criteria, the expected review time and how additional records would be requested. That does not show that these steps are absent; it means prospective patients cannot reconstruct them fully from the pages reviewed. Preparing a current medication list and questions about the assessment is more useful than assuming a short online form is the entire clinical encounter. The first-consultation guide offers a framework for that preparation.
Geography and age also need a service-specific check. Mondae advertises availability in all 50 states, while its terms restrict use to people located in the United States and make eligibility depend on the state and type of service. The terms generally describe access for adults 18 or older, with some services potentially restricted to those over 21. Although they include a parental-consent exception, the privacy policy says it does not knowingly allow under-18 accounts. That conflict does not confirm pediatric treatment.
What the advertised prices actually establish
Mondae publishes concrete prices, but the homepage and product pages do not match. Compounded semaglutide starts at $69 per month on the homepage, compared with $87 per month on its product page. Compounded tirzepatide starts at $114 per month on the homepage, compared with $126 on its product page. Both product pages display one-, three- and six-month choices. The consulted text does not unambiguously connect the displayed price to one choice or explain what qualifies a patient for the lower homepage amount.
The same pattern appears outside the GLP-1 offerings. Sermorelin injection, NAD+ injection and glutathione injection each start at $95, billed monthly, on the homepage; their product pages show $99 per month beside one- and three-month options. The table records those advertisements without treating them as personalized quotes. Neither the plan lengths nor the monthly labels establish shipment quantities, a minimum commitment, mandatory prepayment or a total package charge. Those details require confirmation rather than arithmetic based on an uncertain starting figure.
The product pages advertise no membership fees, one-to-one provider guidance and the same price at every dose. Separately, the homepage says the starting rate lasts while membership remains active and that provider-directed dose changes do not increase the monthly price. That is a conditional commercial promise, not a complete membership agreement. The documentation does not settle which consultations, laboratory work, administration supplies or shipping charges are included, nor how the membership operates without a separately advertised membership fee.
| Offering | Homepage advertisement | Product-page display and plan choices |
|---|---|---|
| Compounded semaglutide | From $69/month | $87/month; 1, 3 or 6 months; price-to-plan association unclear |
| Compounded tirzepatide | From $114/month | $126/month; 1, 3 or 6 months; price-to-plan association unclear |
| Sermorelin injection | From $95; billed monthly | $99/month; 1 or 3 months; price-to-plan association unclear |
| NAD+ injection | From $95; billed monthly | $99/month; 1 or 3 months; price-to-plan association unclear |
| Glutathione injection | From $95; billed monthly | $99/month; 1 or 3 months; price-to-plan association unclear |
The first charge needs a written explanation
Mondae and its providers say they do not accept commercial insurance, are not in-network with commercial plans and do not participate in federal or state healthcare programs such as Medicare and Medicaid. Patients choose the service on a cash-pay basis outside those programs. This describes Mondae’s payment arrangement; it should not be confused with a finding about an individual’s insurance benefits elsewhere. For this service, the important preparation is a written breakdown of the initial payment and any subsequent charges.
There is an unresolved tension over what happens when treatment is not approved. The homepage FAQ says patients will not be charged until a physician approves treatment. The refund policy, however, says telehealth consultation fees are nonrefundable, including when no medication is prescribed. The documentation does not explain whether a consultation fee is collected separately, which situations trigger it or how both statements apply together. A prospective patient should ask specifically what, if anything, can be charged after an unsuccessful evaluation.
The consulted terms also contain an omitted central section, limiting a complete review of payment, treatment availability and termination provisions. Automatic-renewal mechanics, the deadline to stop future charges and the membership cancellation procedure are not established in the available documentation. Before enrolling, request the exact first charge, the next billing date, the amount due at renewal and any separate consultation fees. A statement that pricing stays constant does not resolve when money is collected or how future billing ends.
The pharmacy handoff and compounded-product questions
Mondae identifies compounded semaglutide and compounded tirzepatide as offerings, but the consulted documentation does not establish the exact concentration, presentation, quantity supplied per shipment or specific anatomical administration route. Ingredient names and monthly prices are therefore not a full description of what a patient would receive. Nor does Mondae’s statement that licensed pharmacies dispense medication identify who compounds a particular preparation. These are useful questions for the prescription-to-pharmacy handoff, not details to infer from a product category.
Mondae’s own notice says compounded medications are not FDA approved and are not reviewed by the agency for safety, effectiveness or quality before dispensing. FDA guidance provides the broader context: compounded preparations do not undergo FDA premarket review, and FDA recommends them for patients whose medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. That recommendation is not a blanket judgment about Mondae, and nonapproval alone does not demonstrate clinical inequivalence.
FDA has also reported errors involving measurement or administration of compounded medication, including some associated with hospitalization. That makes clear, product-specific instructions and an identifiable pharmacist important parts of the handoff. This review cannot supply dosing instructions or resolve an individual prescription question. Before shipment, patients can ask who will explain the label and administration materials, how questions reach the dispensing pharmacist, and what to do if the received product differs from the prescription description.
Shipping promises versus a usable delivery plan
Mondae says prescribed medication is shipped directly to the patient’s door with tracking information and describes shipping as quick and discreet. Those statements do not establish a dispatch deadline or arrival date. The consulted documentation does not quantify clinical review, preparation or transit times, identify a carrier, describe shipment frequency or explain temperature-control arrangements. The Shipping & Delivery policy content was unavailable for this review. Patients should therefore distinguish approval, pharmacy processing, dispatch and arrival rather than treating them as one promised turnaround.
For damaged or defective medication, Mondae’s refund policy requires an email report within 48 hours of delivery, with photographs of the medication and original packaging. If the issue is confirmed, the stated remedy is replacement at no additional cost; a refund is offered only if replacement is not possible. For a confirmed wrong medication or incorrect order, the policy says the correct medication will be shipped without additional charge and return instructions may be provided. These remedies are conditional, not automatic refunds.
Temperature concerns also require a clinical safety response, not just a purchase complaint. FDA explicitly advises not using an injectable GLP-1 drug that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. Our warm-delivery guide explains that advice. Mondae’s 48-hour damage-reporting requirement should not be mistaken for permission to use a questionable shipment while awaiting a reply. Obtaining a working pharmacy contact before delivery would make that situation easier to address.
Follow-up, support and communication privacy
Mondae advertises secure messaging with the healthcare provider through an online patient portal throughout treatment. It says patients can raise questions or dosage concerns and request follow-up consultations and clinically appropriate treatment adjustments. This establishes an advertised route back to the clinician, but not a scheduled follow-up cadence, guaranteed response time or unlimited consultation allowance. The documentation also does not settle whether every requested follow-up is included in the advertised monthly amount. Those distinctions matter when comparing ongoing care rather than just enrollment convenience.
Purchase-related support is described as available from 8 a.m. to 8 p.m. Eastern Time, without specified days in that passage. That is not the same as documented clinical coverage during those hours. Contact emails in the consulted material appeared as protected placeholders rather than usable, verifiable addresses. Before purchasing, prospective patients should locate a working support channel, confirm how it differs from provider messaging and ask where time-sensitive medication questions go when the usual clinician is unavailable.
Communication privacy deserves a separate check. Although Mondae describes portal messaging as secure, its terms warn that ordinary text messages and emails are not encrypted and may be intercepted. Its privacy policy also explicitly states that it may sell sensitive personal data, with consent where required. These statements concern different channels and data practices; secure portal messaging does not erase the broader notice. Patients can ask which information should stay inside the portal and what privacy choices are available before submitting detailed health information.
Ending an order is not the same as ending ongoing billing
Mondae’s order policy draws an early cancellation boundary: an order can be canceled only before medication has been dispensed or shipped. Dispensing can therefore close the cancellation window before a tracking update shows movement. For a successfully canceled order before shipping, the policy says a full refund will be issued within five to seven business days. That issuance period does not guarantee the money will appear in a bank account within the same window, and the separate nonrefundable-consultation provision still needs clarification.
Other refund requests follow a different process. Mondae says refunds are not guaranteed and are reviewed only in limited situations. Requests must include an order number, purchase date and explanation, and supporting documentation may be required. The policy states that review occurs within five to seven business days and, if approved, refunds are issued to the original payment method within ten to fourteen business days. These are separate review and issuance stages, not one universal refund deadline for every circumstance.
Canceling a particular order also does not establish how to terminate a membership or prevent a later charge. The consulted documentation does not provide a clear advance-notice deadline or complete ongoing-billing cancellation procedure. A useful final enrollment check is to obtain both processes in writing: how to stop an order before dispensing and how to end future participation. Because the advertised continuing rate depends on active membership, patients should also ask what happens to that rate after a pause or cancellation.
Questions & answers
Does Mondae itself provide medical care?
Its terms say it does not. Mondae operates the platform, while medical services come through contracted physicians and telehealth services through Bask Telehealth LLC. Ask which clinical organization and individual prescriber will be responsible for your care.
Which semaglutide or tirzepatide price should I expect?
That requires a confirmed quote. The homepage lists compounded semaglutide from $69/month and compounded tirzepatide from $114/month; product pages show $87 and $126/month. The relationship between those amounts and the displayed one-, three- or six-month options is unclear. Ask for the selected plan’s payment schedule and included services.
Will Mondae charge me if no prescription is issued?
The public statements do not fully resolve that question. The homepage says no charge occurs until physician approval, but the refund policy calls consultation fees nonrefundable even without a prescription. Obtain a written explanation of any consultation charge before completing the paid portion of enrollment.
Does nationwide availability mean every treatment is available everywhere?
Not necessarily. Mondae advertises all 50 states, but its terms make access depend on the state and type of service and restrict use to people located in the United States. Confirm the particular treatment and clinical service for your location rather than relying only on the nationwide headline.
How do I contact a clinician after medication arrives?
Mondae advertises secure provider messaging through its patient portal and the ability to request follow-up consultations. It does not document a guaranteed response time or routine appointment schedule. Purchase-support hours are separate and should not be read as a promise of clinical availability.
What should I do if a shipment is damaged or warm?
Mondae requires damage or defect reports within 48 hours of delivery, with photos of the medication and original packaging. For an injectable GLP-1 that arrives warm or insufficiently refrigerated, FDA advises not using it and contacting the provider or dispensing pharmacy. Confirm a working contact channel before shipment.
Our assessment
Mondae documents the main stages of a telehealth service: intake, clinician evaluation, conditional prescribing, pharmacy dispensing, tracked home delivery and portal-based follow-up. Its published prices, cash-pay status and order-remedy policies provide useful starting points for comparison. The weaker area is operational specificity. Pharmacy identities, exact product presentations, delivery expectations, clinical response times and the full membership billing process remain unresolved in the consulted documentation. The conflicting price displays and consultation-charge statements are particularly important because they affect what a patient might pay before receiving medication. A practical next step is to request one written summary naming the responsible clinical organization and pharmacy, identifying the prescribed presentation, itemizing the first and recurring payments, and explaining follow-up and cancellation. Mondae’s documented pathway is understandable, but those confirmations are needed to turn its broad service promises into a dependable account of an individual care arrangement.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- Mondae — policies/refunds ↗
- Mondae — official website ↗
- Mondae — treatments/compounded tirzepatide ↗
- Mondae — treatments/glutathione ↗
- Mondae — treatments/nad ↗
- Mondae — policies/privacy policy ↗
- Mondae — treatments/compounded semaglutide ↗
- Mondae — policies/terms of service ↗
- Mondae — treatments/sermorelin ↗